Legal & General Group
VKTX icon

Legal & General Group’s Viking Therapeutics VKTX Stock Holding History

Legal & General Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82M Buy
97,884
+1,351
+1% +$43.6K ﹤0.01% 1705
2026
Q1 		$3.14M Sell
96,533
-11,990
-11% -$385K ﹤0.01% 1724
2025
Q4 		$3.82M Sell
108,523
-3,118
-3% -$110K ﹤0.01% 1708
2025
Q3 		$2.93M Sell
111,641
-11,707
-9% -$349K ﹤0.01% 1825
2025
Q2 		$3.27M Buy
123,348
+6,172
+5% +$162K ﹤0.01% 1752
2025
Q1 		$2.83M Buy
117,176
+9,806
+9% +$310K ﹤0.01% 1794
2024
Q4 		$4.32M Sell
107,370
-745
-0.7% -$42.5K ﹤0.01% 1650
2024
Q3 		$6.84M Buy
108,115
+6,606
+7% +$388K ﹤0.01% 1413
2024
Q2 		$5.38M Buy
101,509
+5,222
+5% +$342K ﹤0.01% 1489
2024
Q1 		$7.9M Buy
96,287
+781
+0.8% +$34.8K ﹤0.01% 1274
2023
Q4 		$1.78M Buy
95,506
+906
+1% +$11.8K ﹤0.01% 2003
2023
Q3 		$1.05M Sell
94,600
-202
-0.2% -$2.89K ﹤0.01% 2169
2023
Q2 		$1.54M Buy
94,802
+64,493
+213% +$1.35M ﹤0.01% 2042
2023
Q1 		$505K Buy
+30,309
New +$313K ﹤0.01% 2314
2022
Q2 		– Sell
-24,729
Closed -$74K – 3664
2022
Q1 		$74K Hold
24,729
– – ﹤0.01% 2931
2021
Q4 		$114K Hold
24,729
– – ﹤0.01% 2883
2021
Q3 		$156K Buy
24,729
+13,023
+111% +$80.5K ﹤0.01% 2753
2021
Q2 		$70K Buy
11,706
+528
+5% +$3.13K ﹤0.01% 2848
2021
Q1 		$70K Buy
11,178
+3,899
+54% +$27.4K ﹤0.01% 2722
2020
Q4 		$41K Hold
7,279
– – ﹤0.01% 2857
2020
Q3 		$42K Sell
7,279
-2,677
-27% -$18.4K ﹤0.01% 2752
2020
Q2 		$72K Buy
9,956
+594
+6% +$3.94K ﹤0.01% 2620
2020
Q1 		$44K Sell
9,362
-3,326
-26% -$20.4K ﹤0.01% 2636
2019
Q4 		$102K Buy
12,688
+981
+8% +$7.15K ﹤0.01% 2588
2019
Q3 		$81K Hold
11,707
– – ﹤0.01% 2591
2019
Q2 		$98K Hold
11,707
– – ﹤0.01% 2539
2019
Q1 		$116K Buy
11,707
+1,003
+9% +$8.39K ﹤0.01% 2449
2018
Q4 		$82K Buy
10,704
+2,945
+38% +$35.2K ﹤0.01% 2509
2018
Q3 		$135K Buy
7,759
+1,264
+19% +$15K ﹤0.01% 2426
2018
Q2 		$62K Buy
+6,495
New +$43.2K ﹤0.01% 2659

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Legal & General Group's VKTX Position: Q2 2026 in Review

Legal & General Group increased its Viking Therapeutics (VKTX) stake by 1.4% in Q2 2026, buying an estimated $43.6K and bringing the position to 97,884 shares worth $3.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1705.

Legal & General Group first reported a position in VKTX in Q2 2018 and has held it in 30 quarters since. The position peaked at $7.9M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Legal & General Group held 97,884 shares of Viking Therapeutics worth $3.82M as of Q2 2026.
  • Legal & General Group bought 1,351 Viking Therapeutics shares in Q2 2026, an estimated $43.6K.
  • Viking Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1705 holding.
  • Legal & General Group first reported a position in Viking Therapeutics in Q2 2018 and has held it in 30 quarters since.
  • Legal & General Group's Viking Therapeutics position peaked at $7.9M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.